The third batch of volume procurement how to quote foreign enterprises.

The third batch of tape procurement (volume-based procurement, replaced by VBP below) is about to begin, VBP has also become the top priority affecting all pharmaceutical companies, as a breakthrough in the new health reform, VBP has become normal, and will not leave a dead endone of the purposes of VBP is to replace the original research drug that has passed the patent protection period with a generic drug that has passed the patent protection period, so in addition to the generic drugs bidding for each other, generic drugs and original research drugs (many belong to foreign enterprises) become the two camps of VBP, and what kind of coping strategies taken by foreign enterprises, not only affect the foreign enterprises' own strategy in China, but also will have a direct impact on the price of generic drugs, this paper on the impact of VBP on the third batch of foreign enterprises to do a possible analysis and analysisand anticipate how foreign enterprises will respond to the third batch of VBp, we also need to understand the impact of the first two VBFs (i.e., 4 plus 7, 4 plus 7 and the second batch of volume procurement) on foreign enterprises and their initiativesAccording to a joint report by FabEr Technology and China Pharmaceutical Market Research Association, foreign companies are still affected by the first two vBP, of which the most affected foreign companies are Sanofi, its related products in Sanofi's sales accounted for 42.4%, followed by Pfizer 33.2%, Bayer 22.3%, which, Sanofi's four products are Porvi (i.eclopidogrere, 29.9 per cent), Ambovi (i.eUbersatin, 5.3 per cent), Amoli (i.eGremequine, 4.3 per cent) and Ambono (i.e., Ebesatan hydrochloroquine, 2.9 per cent)(Figure 1)According to the joint report of FabEr Technology and China Pharmaceutical Market Research Association, in the pilot cities of 4 plus 7, the proportion of sales and sales of non-winning original research products in the corresponding varieties decreased across the board, and the share of sales fell to an average of about 20%The biggest declines in sales were in Uber's Kepplin (left, Ethiresitan) and GSK's Veridod (Tenofovir idiolinere), down as much as 40%, followed by Amberway (i.eUbersatin, Sanofi) 38%, Luxin (i.e., aminechlorodiponan, Pfizer) 33% and Lipto (I.e., Atstaparitin, Pfizer) by 30%(Figure 2)based on objective data simulation, for the short-term (one year after winning the winning bid) sales comparison of the original research products, not the winning bid is better than the winning bid, but taking into account the long-term benefits, will draw different conclusionsIn the face of VBP, foreign companies have also experienced a wait-and-see process to gradually adapt, 4 plus 7 sets of the pilot, 14 foreign companies participated in the bidding, but only 2 original research varieties, namely AstraZeneca (AZ) Gifitini in the second batch of 2017 national health insurance negotiations have reduced prices by 56% on the basis of another 77% price reduction, Squip's Forsinna with a direct price reduction of 70% of the priceBy the time of the expansion of the 4 plus 7, increased to 5 original research results, of which Sanofi at the price of 81% to regain the 4 plus 7 lost chloropip?regray winning the bid and become a 4 plus 7 expansion of the explosion point, and the second batch of VBP when Bayer with a 78% drop in a 78% drop to win the bid of acapo sugar also earned enough eyeballs, become a symbol of foreign companies to further adapt to VBPAfter further verification, the third batch of VBP involved a total of 24 foreign enterprises, of which, the largest number of original research varieties are Mersadon (MSD) and Pfizer, each with 5 varieties, namely, Mercatonon finasteamine, relying on kaxi, ground chlorate 3 A variant of the agent form and Theonuste granules and Monrust chewing tablets, Pfizer's Shecurin, Selysib, Tofatib, linamine 4 oral reactive agent forms and non-medicalized cesina non-tablets(Figure 4) although the patent has expired, but foreign enterprises in the domestic market consistently occupy a larger market share, which is one of the reasons why the country started VBP, the third batch of VBP involved in the original research products are no exception, Figure 5 listed the third batch of VBP involved in the 2019 national public medical institutions sales of 200 million yuan, market share of 40 billion yuan % of the original research drugs, of which, Seloxib (Pfizer), relying on Kauxi (MSD), Vegretin (Novartis) still occupied the entire market, its 2019 national public medical institutions sales of 1.07 billion yuan, 415 million yuan and 244 million yuan, respectively and this most striking when the second batch of VBP was removed from the collection list of metformin, in the third batch of VBP varieties list of metformin oral reamplycem and metformin slow release control agent type appeared, these two varieties are the largest (27 and 16 respectively), but also the VBP varieties list of the largest market, 2019 total sales of up to 5.5 billion yuan The original research of the chang-release dosage form was Shi Guibao (with a market share of 60.1%) and the original research of the slow release agent form was Merck Sherano (with a market share of 6.5%) In addition, in November last year, Hebei urban and rural residents medical insurance clinic co-ordinated two diseases drug band procurement project, metformin to 0.043 yuan / tablet price selected, so this metformin price reduction has no suspense, only to spend who home facing VBP, foreign enterprises from wait-and-see to gradually adapt, although the third batch of VBP foreign companies quotation strategy is not yet known, and the third batch of VBP official rules have not yet been issued, but in the face of the procurement cycle gradually extended (from 1 year to 2-3 years at 4 plus 7) and the network Pass "actual clinical drug use, using non-successful products to cancel the reward" and other rules should be harvested, do not leave a dead end of the VBP rigidity, foreign enterprises to the third batch of VBP participation is no less than the first two vBP, and to improve the winning bid rate, increase the price reduction range is no different choice.